RecruitingNot ApplicableNCT05577585

Ketamine in OCD: Efficacy and Effects on Stress and Cognition

Ketamine Therapy in Obsessive-compulsive Disorder and Its Effects on Neuropsychological Function Under Stress in a Cross-over Trial


Sponsor

Medical University of Vienna

Enrollment

60 participants

Start Date

Oct 1, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

The main goal of this trial is to demonstrate therapeutic efficacy of low dose ketamine in patients with OCD. We expect that ketamine will alleviate symptoms in the hours following application, but also - if effective - that the anti-OCD effects might last for several days after a single infusion.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether ketamine — a medication used in anesthesia that also shows promise in treating mental health conditions — can reduce obsessive-compulsive disorder (OCD) symptoms. It is also examining how ketamine affects stress and thinking ability. **You may be eligible if...** - You have a primary diagnosis of OCD - Your OCD symptoms are significant (score of 16 or higher on the Yale-Brown OCD scale) - You have tried at least one prior treatment for OCD - You can provide written informed consent **You may NOT be eligible if...** - You have a history of psychotic disorders - You have had a manic episode in the past 3 years - You have unstable substance use or dependence (other than nicotine) - You are pregnant or at elevated risk of becoming pregnant - You have severe personality disorder (other than obsessive-compulsive personality) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGKetamine 50 MG/ML Blinded

See also Arm description

DRUGMidazolam

See also Arm description

DRUGKetamine 50 MG/ML Open Label

Open Label Follow Up (up to 8 Infusions)

OTHERTreatment as Usual (TAU)

Treatment as Usual may include psychotherapy, pharmacotherapy, physiotherapy, ergotherapy, or a combination of these-at the discretion of the treating physician, independently of the study.


Locations(1)

Medical University of Vienna, Department of Psychiatry and Psychotherapy

Vienna, State of Vienna, Austria

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05577585


Related Trials